Published in Cancer Res on August 01, 2001
Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut (2006) 1.09
The thiopurines: an update. Invest New Drugs (2005) 1.05
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2012) 1.03
Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. Br J Cancer (2006) 0.95
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood (2005) 0.93
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos (2010) 0.81
TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenet Genomics (2013) 0.79
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS One (2016) 0.79
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics (2014) 0.76
Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers. Mol Cancer Ther (2011) 0.76
Azathioprine-induced hepatitis and cholestasis occurring 1 year after treatment. BMJ Case Rep (2014) 0.75
Improved pharmacokinetics of mercaptopurine afforded by a thermally robust hemihydrate. Chem Commun (Camb) (2016) 0.75
Safety of azathioprine use during pregnancy. Can Fam Physician (2011) 0.75
Assessment of Thiopurine-based drugs according to Thiopurine S-methyltransferase genotype in patients with Acute Lymphoblastic Leukemia. Iran J Ped Hematol Oncol (2014) 0.75
Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev (1998) 12.55
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell (1997) 12.41
The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell (1985) 10.17
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
Sequence of the gene for the constant region of the mu chain of Balb/c mouse immunoglobulin. Gene (1981) 8.45
Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell (1991) 8.00
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev (1993) 7.41
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev (1999) 6.87
Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell (1992) 6.08
Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 5.92
Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol (1999) 5.78
Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A (1998) 5.74
Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene (1997) 5.64
The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J (1999) 5.44
Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med (2000) 5.04
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
Processed pseudogenes: characteristics and evolution. Annu Rev Genet (1985) 4.40
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med (1997) 4.13
Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci U S A (1998) 3.85
Nomenclature for N-acetyltransferases. Pharmacogenetics (1995) 3.59
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst (1999) 3.58
Unexpected relationships between four large deletions in the human beta-globin gene cluster. Cell (1983) 3.57
Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature (1987) 3.37
Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol (1995) 3.19
A mouse alpha-globin-related pseudogene lacking intervening sequences. Nature (1980) 2.92
p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev (2000) 2.74
Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med (1998) 2.59
Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther (2012) 2.48
The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther (2013) 2.40
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med (1997) 2.38
Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol Cell Biol (2000) 2.34
A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene (1995) 2.26
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol (2001) 2.15
Ligand and protein kinase C downmodulate the colony-stimulating factor 1 receptor by independent mechanisms. Mol Cell Biol (1989) 2.12
A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12
Cell surface expression of v-fms-coded glycoproteins is required for transformation. Mol Cell Biol (1984) 2.09
Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics (1992) 1.99
Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol Cell Biol (2001) 1.96
Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia (2000) 1.94
Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood (2000) 1.89
DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol Cell Biol (1995) 1.85
Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol (2001) 1.82
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther (2008) 1.82
The product of the c-fms proto-oncogene: a glycoprotein with associated tyrosine kinase activity. Science (1985) 1.80
Expression of the human c-fms proto-oncogene product (colony-stimulating factor-1 receptor) on peripheral blood mononuclear cells and choriocarcinoma cell lines. J Clin Invest (1986) 1.77
Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J (1993) 1.76
Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood (2000) 1.74
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood (2001) 1.74
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Structural features of the colony-stimulating factor 1 receptor that affect its association with phosphatidylinositol 3-kinase. EMBO J (1990) 1.72
Synthesis of membrane-bound colony-stimulating factor 1 (CSF-1) and downmodulation of CSF-1 receptors in NIH 3T3 cells transformed by cotransfection of the human CSF-1 and c-fms (CSF-1 receptor) genes. Mol Cell Biol (1987) 1.71
Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci U S A (1999) 1.66
Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A (1999) 1.65
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62
Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol Cell Biol (1992) 1.61
Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood (1998) 1.60
Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell (1988) 1.59
Topoisomerase II inhibitor-related acute myeloid leukaemia. Br J Haematol (2000) 1.57
Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development. Cell Growth Differ (1997) 1.57
Rationale and design of Total Therapy Study XV for newly diagnosed childhood acute lymphoblastic leukemia. Ann Hematol (2004) 1.57
p53-Dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol (2005) 1.56
Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst (1996) 1.54
Differential effects of p19(Arf) and p16(Ink4a) loss on senescence of murine bone marrow-derived preB cells and macrophages. Proc Natl Acad Sci U S A (2001) 1.51
Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics (1996) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev (2000) 1.47
Transmembrane orientation of glycoproteins encoded by the v-fms oncogene. Cell (1985) 1.41
Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet (1999) 1.40
INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol (2000) 1.40
Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics (1996) 1.38
An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J Virol (1996) 1.38
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol (2001) 1.38
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2000) 1.37
Inducible, high-level production of infectious murine leukemia retroviral vector particles pseudotyped with vesicular stomatitis virus G envelope protein. Hum Gene Ther (1995) 1.37
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol Cell Biol (1999) 1.35
ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence. Leukemia (2010) 1.34
Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther (2001) 1.33
High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum Gene Ther (1999) 1.33
Molecular cloning of the c-fms locus and its assignment to human chromosome 5. J Virol (1983) 1.33
Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet (1994) 1.32
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol (1994) 1.29
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest (1994) 1.29
A rate limiting function of cdc25A for S phase entry inversely correlates with tyrosine dephosphorylation of Cdk2. Oncogene (1999) 1.29
Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood (1994) 1.29
Novel mammalian cyclins (CYL genes) expressed during G1. Cold Spring Harb Symp Quant Biol (1991) 1.29
Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood (1995) 1.29
Multilineage hematopoietic disorders induced by transplantation of bone marrow cells expressing the v-fms oncogene. Cell (1987) 1.27